EGFR and breast carcinoma: One explanation for the limited success of EGFR TKIs in breast cancer is that following EGFR inhibition, other receptors and/or cell surface proteins activate and/or heterodimerize, which provides alternative growth and survival signaling cascades downstream of EGFR, such as the MEK/MAPK pathway [101] (Figure 1).